Compare Abbott Laboratories (ABT) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs CarMax, Inc — how do they compare? Abbott Laboratories trades at $110.91 (market cap $187.95B), while CarMax, Inc trades at $58.6 (market cap $8.26B). The key difference: Abbott Laboratories is far larger — about 22.8× CarMax, Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| ABT | KMX | |
|---|---|---|
Market Cap | $187.95B | $8.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $62.17 |
52-Week Low | $82.57 | $30.88 |
Enterprise Value | $214.96B | $26.77B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
CarMax (KMX) trades at $58.705, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q2 2025 but beating in Q3 2025 and Q1 2026, with net income of $500.56M in 2025. Recent news includes a Zacks Strong Buy rating and a partnership with Sierra to enhance customer service, though ongoing legal investigations pose a headwind.
The stock's outlook is cautiously optimistic, supported by improving cash flow trends and analyst buy ratings, but risks include high debt levels and margin pressures. With a consensus price target of $53.09 below the current price, near-term upside may be limited despite positive momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
